NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. - Wikidata - wikimedia - TriplyDB

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

http://www.wikidata.org/entity/Q37275182

about

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus Genome sequencing identifies a basis for everolimus sensitivity The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.A neuronal function of the tumor suppressor protein merlin Merlin Isoforms 1 and 2 Both Act as Tumour Suppressors and Are Required for Optimal Sperm Maturation Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival Current issues in malignant pleural mesothelioma evaluation and management Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation.Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.Optimizing biologically targeted clinical trials for neurofibromatosis.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.Hereditary genodermatoses with cancer predisposition ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.Functional annotation of proteome encoded by human chromosome 22.Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1)Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.The mTOR signaling pathway as a treatment target for intracranial neoplasms Frontier of epilepsy research - mTOR signaling pathway.FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function.Neurofibromatosis-related tumors: emerging biology and therapies.Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation.Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

P2860

Q24300692-65623891-7064-464D-B4B6-79A80C892647 Q24631915-DCB3D002-FBD7-4D37-9628-0BA12D99CCB6 Q26783814-D30ED6FC-FED0-4E56-B46E-6C83DEC30EF6 Q26825296-394C02A7-6F37-4D73-A342-24DAEA64607F Q26830181-11FAE918-3D5F-49A1-ABA3-D7A83EA459C7 Q27304868-B62ED2DD-CBE0-4467-B16B-1EE1A83C55C6 Q27853117-0C59E946-CEC5-4D29-92C4-AFE2F1BE9E9A Q27853151-69BD8267-E7B0-43BD-87CF-6B91FBFF852B Q28283076-47110735-6075-48E5-A645-26060989A4E5 Q28393560-CE92F5D0-5AC0-420C-9A6E-CC7289F955E8 Q28728224-E2A88907-D04F-4063-8B7F-ADD5C8D125A3 Q30389069-BF6ABCA0-5B27-4C95-A4C9-B8DB26A86945 Q30396975-2B337569-DF1C-41C9-AF81-610D06016D3E Q30401833-464F465B-311A-4C96-8666-E6DEDAB65008 Q30415483-0964070C-FDF4-4ED1-92C0-C405F84F0A7F Q30419586-9F5ED076-06F6-48F4-B3A7-3F1EB30A1235 Q30422022-EFD46A2F-2C75-49DB-B52D-219735DCD05C Q30437229-D9176DB2-2784-4364-8795-A2729BEABD60 Q30438898-A0163FAA-55EA-4C7D-B18A-D6996C21794F Q30440530-1F535B42-7422-4F2C-B9D7-15C4F6B1685C Q30456266-E85C6D0F-DC0A-4621-B295-D81C4E7F3F60 Q30464280-B73FEC74-EC91-4E4A-85F8-D63EF886E1BE Q30470596-17C0B305-DF43-4068-9CEE-70928588A094 Q30474678-2DA04453-F834-4024-BC54-3C3052AF1FBD Q33414370-1F91BA81-2218-41FA-80E6-9E8C50073DB8 Q33591646-376E21ED-24DB-48A0-A0B9-73610F565194 Q33745071-5E138C1F-4788-4DB1-9A63-2CBE917AB146 Q33761772-7448220A-BABC-4111-BC96-5B7B42EF2985 Q33819404-7BBFBE52-2273-498A-8D02-E17BE3780A25 Q34062012-C6C8A8DA-FA82-499E-9EC8-ABA2F0BDEE94 Q34620864-F0984868-05F4-46FF-8D9C-356BB9D5EFF4 Q34716061-23FB28E6-1042-40A3-B208-786D336AA1B0 Q34886859-A0309C79-72C2-480D-9DA5-E933AFADF5AA Q35014198-BA41924E-A7EF-4CA9-8449-7B8333AF811B Q35096540-7D135EA5-1847-4338-A387-3B62E3E9801D Q35218073-7A0FA161-7D90-4CAE-B2D6-67F2C382D517 Q35562786-74B597D7-DF65-4F72-8F74-C069CF81D5CE Q35569915-9F6A2E26-06EB-4D1C-9806-697F5E829A3F Q35670477-0CA4DACA-E330-4ED4-93F3-7D844ED58F98 Q35793582-B95E1ED1-28AE-426F-B8DC-D8C127631616

P2860

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

http://www.wikidata.org/entity/Q37275182

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@en

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@nl

type

label

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@en

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@nl

prefLabel

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@en

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@nl

P1433

Q37275182-21C53448-D8A1-4A1D-B7A1-D71F405F5336

P1476

Q37275182-8633E1A8-EC6D-4851-A12C-E67BCAE2BA58

P2093

Q37275182-07B042DF-1324-4FE9-84C0-117D404A43A4

Q37275182-2B522F92-FBAA-45C8-A091-1A8E53C7C90D

Q37275182-59485FDD-537B-4CCE-AA28-99647C2D1C15

Q37275182-6CE5CC13-76D3-424D-8132-7F74D715D345

Q37275182-6F25604F-0D9F-49CE-A4CB-562F20DC4EEF

Q37275182-733922CC-C725-4542-AB4A-D44E03D347BC

Q37275182-8CF8EEA5-2633-41C3-9423-46FF199BF1EF

P2860

Q37275182-00C00668-6A40-42B3-9206-7ADCEB07C5AF

Q37275182-02C02A23-A4E3-4B9E-9CA4-2B872805F5DE

Q37275182-0406AF15-057B-4129-9959-4E47505113BE

Q37275182-04371AB6-9A43-483C-BDF2-49272C1D54A8

Q37275182-09E00DC5-471E-41B2-A96A-2C9FF187E6BB

Q37275182-0ABA8C90-7C47-4842-9107-8AB2192ABD77

Q37275182-1821DDD7-197B-42EC-B1A6-331B21227E3D

Q37275182-2AE339B6-BD12-4057-A93A-33FFA14658C1

Q37275182-2D0440E7-4015-4A74-837C-D671F9C192AD

Q37275182-30C22723-737E-40B6-BBA0-3DF93315227A

P304

Q37275182-BEA95A23-2438-4308-A216-19D129886888

P31

Q37275182-5137312D-A90E-412A-A457-DB75D110368E

P356

Q37275182-7F790DB5-65FE-4466-B559-86428DF98449

P407

Q37275182-9AF62190-8786-40FF-A123-CF1F39F6B753

P433

Q37275182-246A228F-FCB8-4E2B-9EF6-A00F7DDAED00

P478

Q37275182-1C72A21E-EAA6-4197-AA53-CC5DFCA669BB

P50

Q37275182-4E347269-BB68-4764-8B91-2EECDBCC46CD

P577

Q37275182-9C1A1B75-399C-4318-B184-2D0263370D54

P5875

Q37275182-091654E8-E877-4FEB-B9FF-5BE3EA45A276

P698

Q37275182-B68622D3-0CE9-41D4-AFEA-4E080900C28C

P932

Q37275182-19ADAD33-DD41-46E2-B578-3015683C2553

P356

P1433

Molecular and Cellular Biology

P1476

NF2/merlin is a novel negative ...... ingioma and schwannoma growth.

@en

P2093

Anat O Stemmer-Rachamimov

http://www.w3.org/2001/XMLSchema#string

Brendan D Manning

http://www.w3.org/2001/XMLSchema#string

Carolyn Polizzano

http://www.w3.org/2001/XMLSchema#string

Marianne F James

http://www.w3.org/2001/XMLSchema#string

Sangyeul Han

http://www.w3.org/2001/XMLSchema#string

Scott R Plotkin

http://www.w3.org/2001/XMLSchema#string

Vijaya Ramesh

http://www.w3.org/2001/XMLSchema#string

P2860

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2

The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

P304

4250-4261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/MCB.01581-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

James F. Gusella

P577

2009-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24436048

http://www.w3.org/2001/XMLSchema#string

P698

19451225

http://www.w3.org/2001/XMLSchema#string

P932

2715803

http://www.w3.org/2001/XMLSchema#string